Investors fear Pelosi’s drug price plan will kill small biotech firms
Private equity investors are lobbying against Nancy Pelosi’s sweeping drug pricing bill, telling her legislative aides in a series of private meetings in recent weeks that the plan would dry up financing for small biotech companies.
